









# **SMML** newsletter

October 2023

Based on data from September 2023

Monthly updates around multiple myeloma























The goal of this newsletter is to give an overview of what is happening around multiple myeloma in terms of medical developments. This is achieved by monitoring news articles, PR releases and scientific reports on one hand. Conversations from HCPs, digital opinion leaders and other influencers attending congresses, offering their opinion on treatments and commenting on new developments on the other hand.





### Who will benefit from this newsletter?

Any professionals interested in keeping up with developments around multiple myeloma:


- Marketers
- **Business Analysts**
- But also HCPs who want to anticipate the future landscape of MM management




Introduction on Multiple Myeloma

## What is Multiple Myeloma?











## **Read more on Multiple Myeloma:**




- → Professional version in English
- → Professional version in French



- → Consumer version in English
- → Consumer version in French

## MM lines of therapy based on to the following definitions





## Drugs approved by European Medicines Agency (EMA) & FDA

	U

**Click here** 

Prolia® / Xgeva®

**Click here** 

Brand name	Active substance	Manufacturer	Class of therapy	EMA Date of authorisation	Line of treatment	Product Monograph
Revlimid®	lenalidomide	BMS	Immunomodulating agents (IMiDs)	14/06/2007	All lines	Click here
Thalidomide® / Thalomid® (US)	thalidomide	BMS	Immunomodulating agents (IMiDs)	16/04/2008	All lines	Click here
Imnovid® / Pomalyst® (US)	pomalidomide	BMS	Immunomodulating agents (IMiDs)	05/08/2013	2L+ (after Revlimid and Velcade)	Click here
Pepaxti® / Pepaxto® (US)	melflufen	Oncopeptides AB	Peptide conjugated alkylator	17/08/2022	Triple class exposed / 3L+ / 4L+ / 5L+	Click here
Velcade®	bortezomib	Janssen	Proteasome inhibitors (PIs)	26/04/2004	1LSCT / 1LNSCT	Click here
Kyprolis®	carfilzomib	Amgen	Proteasome inhibitors (PIs)	19/11/2015	2L+ / 3L+	Click here
Ninlaro®	ixazomib	Takeda	Proteasome inhibitors (PIs)	21/11/2016	2L+	Click here
Farydak <sup>®</sup>	panobinostat	Novartis + (Secura Bio)	Histone deacetylase inhibitors (HDACis)	28/08/2015	2L+ Relapsed / Refractory	Click here
Darzalex®	daratumumab	Janssen	Monoclonal antibody against CD38 (Mabs)	20/05/2016	All lines	Click here
Empliciti <sup>®</sup>	elotuzumab	BMS + (AbbVie)	Monoclonal antibody against SLAMF7 (Mabs)	11/05/2016	2L+ / 3L+	Click here
Sarclisa®	isatuximab	Sanofi	Monoclonal antibody against CD38 (Mabs)	30/05/2020	2L+ / 3L+	Click here
Tecvayli®	teclistamab-cqyv	Janssen	Bispecific B-cell maturation antigen (BCMA)-directed CD3 T-cell engager	21/07/2022	4L+ (1Pi + 1 IMiDs + 1anti-CD38 Mabs)	Click here
Talvey®	talquetamab-tgvs	Janssen	Bispecific antibody targeting GPRC5D receptor	09/08/2023 (FDA)	4L+ (1Pi + 1 IMiDs + 1anti-CD38 Mabs)	Click here
Elrexfio <sup>®</sup>	elranatamab-bcmm	Pfizer	Bispecific B-cell maturation antigen (BCMA)-directed CD3 T-cell engager	14/08/2023 (FDA)	4L+ (1Pi + 1 IMiDs + 1anti-CD38 Mabs)	Click here
Blenrep® / Belamaf® (US)	belantamab mafodotin-blmf	GSK	Antibody-drug conjugates (BCMA)	25/08/2020	2L+ (4L+ after P, IMiD and MAB (L5+ in Italy)	Click here

Farydak <sup>®</sup>	panobinostat	Novartis + (Secura Bio)	Histone deacetylase inhibitors (HDACis)	28/08/2015	2L+ Relapsed / Refractory	Click here
Darzalex®	daratumumab	Janssen	Monoclonal antibody against CD38 (Mabs)	20/05/2016	All lines	Click here
Empliciti <sup>®</sup>	elotuzumab	BMS + (AbbVie)	Monoclonal antibody against SLAMF7 (Mabs)	11/05/2016	2L+ / 3L+	Click here
Sarclisa®	isatuximab	Sanofi	Monoclonal antibody against CD38 (Mabs)	30/05/2020	2L+ / 3L+	Click here
Tecvayli®	teclistamab-cqyv	Janssen	Bispecific B-cell maturation antigen (BCMA)-directed CD3 T-cell engager	21/07/2022	4L+ (1Pi + 1 IMiDs + 1anti-CD38 Mabs)	Click here
Talvey®	talquetamab-tgvs	Janssen	Bispecific antibody targeting GPRC5D receptor	09/08/2023 (FDA)	4L+ (1Pi + 1 IMiDs + 1anti-CD38 Mabs)	Click here
Elrexfio®	elranatamab-bcmm	Pfizer	Bispecific B-cell maturation antigen (BCMA)-directed CD3 T-cell engager	14/08/2023 (FDA)	4L+ (1Pi + 1 IMiDs + 1anti-CD38 Mabs)	Click here
Blenrep® / Belamaf® (US)	belantamab mafodotin-blmf	GSK	Antibody-drug conjugates (BCMA)	25/08/2020	2L+ (4L+ after P, IMiD and MAB (L5+ in Italy)	Click here
Nexpovio® / Xpovio® (US)	selinexor	Karyopharm Therapeutics	Nuclear export inhibitor (SINE)	26/03/2021	Penta-refractory (2xPI + 2xIMiDs + 1 Mab)	Click here
Venclyxto® / Venclexta® (US)	venetoclax	AbbVie	B-cell lymphoma 2 (BCL-2)	04/12/2016	2L+ (already used in CLL / AML treatments)	Click here
Abecma®	idecabtagene vicleucel	BMS	Cell-based gene therapy (CAR-T)	18/08/2021	Triple class exposed / 3L+ / 4L+ / 5L+	Click here
Carvykti <sup>®</sup>	ciltacabtagene autoleucel	Janssen	Cell-based gene therapy (CAR-T)	25/05/2022	L3 / L4+ / L5+	Click here
Aredia®	pamidronate	Novartis	Bisphosphonates for bone disease	31/10/1991	Supportive care / Long-term use (5+ years)	Click here

20/03/2001

30/07/2009

26/05/2010 - 13/07/2011 Supportive care

Supportive care

Supportive care / Long-term use (5+ years)

Bisphosphonates for bone disease

Bisphosphonates for bone disease

Stem cell mobilazor

Zometa®

Mozobil®

Prolia® + Xgeva®

zoledronate

denosumab

plerixafor


**Novartis** 


Amgen

Genzyme

# MM treatment history timeline







### MM studies at APLUSA







per wave per country per year

4,5K **PATIENTS CHARTS** per wave

18k PATIENTS CHARTS per year (in EU5)



### Launching of a US pilot wave, Why?

- Needs from clients for MM US data
- Back data for EU5 for 15 years
- MM US market changing fast
- Different needs in the US market for labs (patients' ethnicity treatments gap as an example)
- Japan data soon available

### APLUSA's added value

- Quarterly + month to month data collection (our competitors → only quarterly data)
- Market adaptability: adjusting our questionnaires and updating the list of treatments by including market trends on a monthly basis → **new CAR-Ts + BisAbs**
- Patient's full treatment history
- Deliverables with Power BI DID



September 2023





## CONTENTS

**News around clinical** trials in phase II

Phase II relapse/refractory: CAR-T

02.

News around clinical trial s in Phase III

- Phase III relapse/refractory: doublet therapy
- Phase III relapse/refractory: CAR-T

03.

Themes of discussion : HCPs

- SOV Themes of discussion
- Posts driving most engagement
- Focus on #IMS2023

04.

**News articles** overtime

- Volume of articles per volume of mentions
- Articles per themes

05.

Market watch

Market watch





# **SCOPE**



The scope of the analysis is focused on mentions coming worldwide.\*



There were a total of 32K mentions from patients recorded during the listening period from September 1st, 2023, to September 30th, 2023.




A majority of mentions came from News (formerly Twitter) (49%), X (formally known as Twitter) (44%), Forums (2%), Instagram (2%), Reddit (2%) and Blogs (1%).



A total of 9K unique authors were identified.

\*myeloma OR multiplemyeloma OR #mmsm OR #Myeloma\* OR #Curemyeloma\* OR #mmmrd OR #mmsm OR title: ("multiple myeloma" OR myeloma)



Social media listening period : September 2023 Scope: worldwide in English

SYNDICATED BY

## Drugs in clinical trials (Phase II) monitored during the listening period

. . . .

				•	• • •
Molecule name	Commercial name	Class	Manufacturer	Trial names + link (ctrl + right click) / line of treatment / Coml	pination being studied
lenalidomide	Revlimid <sup>®</sup>	immunomodulatory drugs (IMiDs)	BMS	GRIFFIN (ND): daratumumab, lenalidomide, bortezomib, and dexamethasone (D-RVd); FORTE (daratumumab, dexamethasone; NCT02969837 (ND): elotuzumab, carfilzomib, lenalidomide, decamethasone, lenalidomide, daratumumab, carfilzomib	
pomalidomide	Imnovid® / Pomalyst® (US)	immunomodulatory drugs (IMiDs)	BMS	NCT03590652 (RR): daratumumab, ixazomib, pomalidomide, dexamethasone; ELOQUENT-3 (R	R): elotuzumab plus pomalidomide

CAR T-Cell Therapy Anti-BCMA

Bispecific Antibody anti-BCMA

small-molecule PDC

BCL-2

**Bispecific antibody T-cell redirecting** 

Bispecific Antibody anti-BCMA x Anti-CD3

Bispecific Antibody anti-BCMA x Anti-CD3

N/A

N/A

N/A

N/A

N/A

Venclyxto®

Tecvayli®

Elrexfio<sup>®</sup>

NXC-201

teclistamab

talquetamab

REGN5458

Iopofosine

venetoclax

elranatamab (PF-06863135)

mezigdomide (CC-92480)

examethasone; ELOQUENT-3 (RR): elotuzumab plus pomalidomide, Velcade® Proteasome inhibitors Takeda GRIFFIN (ND): daratumumab, lenalidomide, bortezomib, and dexamethasone (D-RVd); NCT03314181 (RR): Venetoclax, Bortezomib Daratumumab and Dexamethasone (With and Without Bortezomib)

carfilzomib Kyprolis® Proteasome inhibitor **Amgen** FORTE (ND): carfilzomib, lenalidomide, daratumumab, dexamethasone; NCT02969837 (ND): elotuzumab, carfilzomib, lenalidomide, dexamethasone; MASTER (/): dexamethasone, lenalidomide, daratumumab, carfilzomib <u>Cardamon</u> (/): cyclophosphamide, dexamethasone, carfilzomib daratumumab Darzalex® Monoclonal antibody anti-CD38 Janssen GRIFFIN (ND): daratumumab, lenalidomide, bortezomib, and dexamethasone (D-RVd); FORTE (ND): carfilzomib, lenalidomide, daratumumab, dexamethasone; NCT03590652 (RR): daratumumab, ixazomib, pomalidomide, dexamethasone REBUILD (RR): Monotherapy; NCT03314181 (RR): Venetoclax, Daratumumab and Dexamethasone (With and Without Bortezomib); MASTER (/): dexamethasone, lenalidomide, daratumumab, carfilzomib; RedirecTT-1 (RR): Teclistamab, talquetamab, daratumumab

(Note: Phase I/II currently in phase IB) ELOQUENT-3 (RR): elotuzumab plus pomalidomide, and dexamethasone; NCT02969837 (ND): elotuzumab, carfilzomib, BMS/AbbVie Empliciti® Monoclonal antibody SLAMF7 lenalidomide, dexamethasone

elotuzumab isatuximab Sarclisa® Monoclonal antibody anti-CD38 Sanofi NCT05123131 (ND): isatuximab, bortezomib, lenalidomide, dexamethasone; NCT03590652 (RR): daratumumab, ixazomib, pomalidomide, dexamethasone belantamab mafodotin, (GSK2857916) Blenrep<sup>®</sup> Antibody drug-conjugate (ADC) **GSK** DREAMM-2 (RR): Monotherapy

cesnicabtagene autoleucel (ARI0002h) N/A Humanised CAR T-Cell Therapy Anti-BCMA N/A NCT04309981 (RR): Monotherapy ciltacabtagene (cilta cel, JNJ 68284528) CAR T-Cell Therapy Anti-BCMA CARTITUDE (RR): Monotherapy; CARTITUDE 2 (RR): Monotherapy

Humanised CAR T-Cell Therapy Anti-BCMA IASO Bio + Innovent FUMANBA-1 (RR): Monotherapy CAR T-Cell Therapy Anti-BCMA KarMMa-2 (RR): Monotherapy (one arm with lenalidomide); BMTCTN1902 (/): Monotherapy

N/A CAR T-Cell Therapy Anti-BCMA N/A CAR T-Cell Therapy Anti-BCMA Cellular Biomedicine

equecabtagene Autoleucel idecabtagene vicleucel (ide cel) zevorcabtagene autoleucel (zevor cel)

N/A CAR T-Cell Therapy Anti-BCMA Arcellx, Inc NCT05396885 (RR): Monotherapy

Nexcella

Janssen

Janssen

Pfizer

**BMS** 

AbbVie

Regeneron

NCT04720313 (RR): Monotherapy

Clover 1 (/)

MajesTEC-1: (RR): Monotherapy; RedirecTT-1 (RR): Teclistamab, talquetamab, daratumumab

MagnetisMM-9 (RR): Monotherapy; MagnetisMM-3 (RR): Monotherapy

NCT03374085 (RR): monotherapy and in combination with dexamethasone

LINKER-MM1 (RR): Monotherapy (Note: phase I/II)

MonumenTAL-1 (RR): Monotherapy: RedirecTT-1 (RR): Teclistamab, talquetamab, daratumumab

NCT03314181 (RR): Venetoclax, Daratumumab and Dexamethasone (With and Without Bortezomib)

# Phase II Relapse/Refractory CAR-T: Innovent and IASO Bio Present Updated Long-Term Follow-Up Data for BCMA CAR-T FUCASO® (Equecabtagene Autoleucel) at IMS 2023



## Headlines/Hot off the press



Innovent and IASO Bio Present Updated Long-Term Follow-Up Data for BCMA CAR-T FUCASO® (Equecabtagene Autoleucel) at IMS 2023

"Innovent Biologics, Inc. a world-class biopharmaceutical company that develops, manufactures and commercializes high-quality medicines for the treatment of oncology, metabolic, autoimmune, ophthalmology and other major diseases, and IASO Bio, a biopharmaceutical company engaged in discovering, developing, manufacturing and marketing innovative cell therapies and antibody products, today announced updated long-term follow-up data from two studies for BMCA CAR-T: (1) Results from phase 1b/2 study (FUMANBA-1) in patients with relapsed/refractory multiple myeloma (RRMM) treated with Equecabtagene Autoleucel (Abstract Code P-290) and (2) A model to predict the risk of prolonged thrombocytopenia recovery in relapsed/refractory multiple myeloma patients after anti-BCMA CAR-T Treatment (Abstract Code P-288) at the 2023 International Myeloma Society (IMS) Annual Meeting in Vienna on September 27-30, 2023." Click here to read the full article

### Sponsor



#### **FUMANBA-1**

Ctrl + click to access clinical trial: NCT05066646

"A Phase 1/2 Study of a Fully Human BCMA-targeting CAR (CT103A) in Patients With Relapsed/Refractory Multiple Myeloma"

### Molecule

**Equecabtagene Autoleucel** 





## Drugs in clinical trials (Phase III) monitored during the listening period

Bispecific Antibody anti-BCMA x Anti-CD3

peptide conjugated alkylating

BCL-2

Molecule name

elranatamab (PF-06863135)

Melphalan flufenamide

venetoclax

Elrexfio®

Venclyxto

melflufen, Pepaxto, pepaxti

**Commercial name** 

Trial names + link (ctrl + right click) / line of treatment / Combination being studied

MagnetisMM-5 (RR): Monotherapy or doublet therapy with daratumumab; MagnetisMM-7 (ND): Monotherapy

molecule name	commercial manie	Class	iiiaiiaiaetai ei	That names : mix (car : Tibre chex) / mic of the athletic / combination semigroups
lenalidomide	Revlimid <sup>®</sup>	immunomodulatory drugs (IMiDs)	BMS	DETERMINATION (RR): lenalidomide (Revlimid), bortezomib (Velcade), and dexamethasone (RVD)  MAIA (ND): daratumumab in combination with lenalidomide and dexamethasone  ATLAS (Maintenance): Lenalidomide, Carfilzomib, Dexamethasone  DRAMMATIC (/): Lenalidomide, Daratumumab  EQUATE (ND): daratumumab, bortezomib, lenalidomide and dexamethasone  POLLUX (RR): Daratumumab, Lenalidomide, and Dexamethasone  TOURMALINE-MM1 (RR): Ixazomib Plus Lenalidomide and Dexamethasone  TOURMALINE-MM2 (ND): Ixazomib Plus Lenalidomide and Dexamethasone  Myeloma XI (ND): cyclophosphamide, dexamethasone plus lenalidomide with or without carfilzomib  AURIGA (Maintenance): Daratumumab Plus Lenalidomide
pomalidomide	Imnovid® / Pomalyst® (US)	immunomodulatory drugs (IMiDs)	BMS	ICARIA-MM (RR): Isatuximab, Pomalidomide, Dexamethasone
bortezomib	Velcade®	Proteasome inhibitors (PIs)	Takeda	DETERMINATION (RR): lenalidomide (Revlimid), bortezomib (Velcade), and dexamethasone (RVD)  BOSTON (RR): selinexor plus bortezomib (Velcade) plus low-dose dexamethasone (SVd)  EQUATE (ND): daratumumab, bortezomib, lenalidomide and dexamethasone  CASTOR (RR): Daratumumab, Bortezomib and Dexamethasone  Bellini (RR): venetoclax plus bortezomib and dexamethasone  DREAMM 7 (RR): Belantamab Mafodotin, Bortezomib and Dexamethasone
carfilzomib	Kyprolis®	Proteasome inhibitors (PIs)	Amgen	IKEMA (RR): Isatuximab, Carfilzomib And Dexamethasone ATLAS (Maintenance): Carfilzomib, Lenalidomide, Dexamethasone Myeloma XI (ND): cyclophosphamide, dexamethasone plus lenalidomide with or without carfilzomib
ixazomib	Ninlaro®	Proteasome inhibitors (PIs)	Takeda	OPTIMUM (RR): Ixazomib, Lenalidomide TOURMALINE-MM1 (RR): Ixazomib Plus Lenalidomide and Dexamethasone TOURMALINE-MM2 (ND): Ixazomib Plus Lenalidomide and Dexamethasone
Bb2121, Idecabtagene vicleucel	Abecma®	CAR T-cell therapy	BMS	KarMMa-3 (RR): Monotherapy
ciltacabtagene	Carvykti®	CAR T-cell therapy BCMA-directed	Janssen	CARTITUDE-4 (RR): Monotherapy

Manufacturer

ciltacabtagene	Carvykti <sup>®</sup>	CAR T-cell therapy BCMA-directed	Janssen	CARTITUDE-4 (RR): Monotherapy
daratumumab	Darzalex®	Monoclonal antibody anti-CD38	Janssen	MajesTEC-3: (RR): Teclistamab in Combination With Daratumumab Subcutaneously (SC) (Tec-Dara)  MAIA (ND): daratumumab in combination with lenalidomide and dexamethasone  DRAMMATIC (/): Lenalidomide, Daratumumab  EQUATE (ND): daratumumab, bortezomib, lenalidomide and dexamethasone  CASTOR: (RR): Daratumumab, Bortezomib and Dexamethasone  POLLUX (RR): Daratumumab, Lenalidomide, and Dexamethasone  MagnetisMM-5 (RR): Monotherapy or doublet therapy with daratumumab  AURIGA (Maintenance): Daratumumab Plus Lenalidomide
isatuximab	Sarclisa®	Monoclonal antibody anti-CD38	Sanofi	IKEMA (RR): Isatuximab, Carfilzomib And Dexamethasone ICARIA-MM (RR): Isatuximab, Pomalidomide, and Dexamethasone
belantamab mafodotin-blmf	Blenrep® / Belamaf® (US)	Antibody-drug conjugates (BCMA)	GSK	DREAMM-3 (RR): Monotherapy DREAMM 7 (RR): Belantamab Mafodotin, Bortezomib and Dexamethasone DREAMM 8 (RR): Belantamab Mafodotin Plus Pomalidomide and Dexamethasone
teclistamab	N/A	Bispecific Antibody anti-BCMA	Janssen	MajesTEC-3 (RR): teclistamab, daratumumab Subcutaneously (SC) (Tec-Dara)

**OCEAN** (RR) : Monotherapy

Bellini (RR): venetoclax plus bortezomib and dexamethasone

**CANOVA** (RR): venetoclax plus Dexamethasone

**Oncopeptides AB** 

AbbVie

Phase III Relapse/Refractory Doublet Therapy: Data did not demonstrate that the treatment combination significantly improved progression-free survival (PFS), the primary endpoint of the trial.

"



## Headlines/Hot off the press

AbbVie Presents Results from Phase 3 CANOVA Study of Venetoclax in Patients with Relapsed or Refractory Multiple Myeloma

"AbbVie today announced data from its Phase 3 CANOVA study evaluating the safety and efficacy of venetoclax (VENCLEXTA®/ VENCLYXTO®) plus dexamethasone (VenDex) for patients with t(11;14)-positive relapsed or refractory (R/R) multiple myeloma who have received two or more prior treatments. **Data did not demonstrate that the treatment combination significantly improved progression-free survival (PFS)**, the primary endpoint of the trial. Patients receiving VenDex showed improvement in median PFS of 9.9 months compared to 5.8 months with the combination of study comparator pomalidomide and dexamethasone (PomDex); however, the results did not reach statistical significance [HR = 0.823, 95% CI: (0.596, 1.136); p-value of 0.237]." Click here to read the full article

Sponsor

abbyie

### **CANOVA**

Ctrl + click to access clinical trial: NCT03539744

"A Study Designed to Evaluate the Safety and Efficacy of Venetoclax Plus Dexamethasone (VenDex) Compared With Pomalidomide Plus Dexamethasone (PomDex) in Participants With t(11;14)-Positive Relapsed or Refractory Multiple Myeloma."

### Combinations

venetociax + dexamethasone





# Phase III Relapse/Refractory CAR-T: 2seventy bio Announces Strategic Restructuring to Prioritize Growth of Abecma, Streamline Pipeline Advancement and Preserve Financial Runway



## Headlines/Hot off the press

2seventy bio Announces Strategic Restructuring to Prioritize Growth of Abecma, Streamline Pipeline Advancement and Preserve Financial Runway

"Approximately 40% workforce reduction combined with related actions expected to achieve \$130+ million savings in the 2024-2025" Click here to read the full article

Sponsor

2seventybio 7

+

Bristol Myers Squibb

KarMMA-3

Ctrl + click to access the clinical trial: NCTO3651128


"Efficacy and Safety Study of bb2121 Versus Standard Regimens in Subjects With Relapsed and Refractory Multiple Myeloma (RRMM) (KarMMa-3)" Molecule

idecabtagene vicleucel





This month most conversations from HCPs were focused on the 20th IMS congress which took place in Athens as well as virtually this year from the 27<sup>th</sup> to the 30<sup>th</sup> of September.

### SOV topics of conversations





### SOV molecules














## #IMS23 Focus



The most mentioned clinical trial was **CANOVA** comparing the combinations PomDex vs. **VenDex**.

The study found **no significant differences in PFS** between the two combinations. The results, anticipated by HCPs, were ultimately deemed **surprising** and **disappointing**.

#### **Volume of mentions**






daratumumab

ianssen

teclistamab

**Janssen** 

#### Topics of discussions (type of treatment)



HCPs multiple myeloma ASCO 2023 universe N= 1 014 mentions Social media listening period: May 26th, 2023, to June 20th, 2023 Scope: worldwide in English

presentation Kuman poster high-risk research Most mentioned clinical trials 12 CANOVA **GRIFFIN** MajesTEC-1 CARTITUDE-4 sanofi janssen Janssen abbvie Janssen **Most mentioned molecules** 83 22

venetoclax

abbvie

talquetamab

Janssen

idecabtagene

vicleucel

Bristol Myers Squibb

#### **Reactions to the CANOVA trial results**



Hira Mian 📀 @HiraSMian • 29 sept.

This is actually very surprising! But the data is what it is and we have to accept it the way it is



ahul Banerjee, MD, FACP @RahulBanerjeeMD · 29 sept.

#IMS23 all of our heads are spinning right now, though!

If you look at time to next treatment, a clear benefit to ven-dex. Idea is that some pts on pom-dex came off study for another #MMsm Tx before formal PD.

OS numerically favors ven-dex, but data not mature.



ten T Peterson PharmD RCOP @KDetersonDharmD . 90 cent

Absolutely excellent discussion within this thread. This study and it's' results give me pause and I look forward to discussing this with the providers in our clinic.



Will I continue to use venetoclax for 11:14?

On a case by case basis, after utilizing CD38 therapies- YES, after a thorough discussion with patients, and using a lower dose (400mg), with careful infection precautions.

Am I disappointed?

Yes

But is ventoclax a game-changer

NIa


SYNDICATED

Engagement was shared between Drs. Abbasi, Rajkumar and Hadidi who posted about personal achievements, educational posts as well as a new tool aimed at helping track disease progression.

Dr. Rajkumar introduced a website MyelomaRisk that aims at helping estimate the risk of progression in Myeloma, smoldering multiple myeloma and MGUS.

Dr. Hadidi received the young investigators award at IMS2023 for work he did on secondary malignancies in long term patients. AL summary of this work can be found <a href="https://example.com/here">here</a>.

Dr. Abbasi posted a series of educational posts about what is multiple myeloma. This is aimed at medical residents.



## Media (press releases): volume and articles per peak





"Multiple Myeloma Story Applied **Cells Opens CellQuest Research Grant** to Accelerate Cutting-Edge Multiple Myeloma Research". <u>Link</u>

"Multiple Myeloma March returns to Cornwall Sept. 9" <u>Link</u>

"Gracell Biotechnologies to Present Updated Clinical Data on BCMA/CD19 Dual-Targeting FasTCAR-T GC012F in Newly Diagnosed Multiple Myeloma at the 2023 International Myeloma Society Annual Meeting" <u>Link</u>

"Immune system plays vital role in longer multiple myeloma remission, new study shows" <u>Link</u>

**B** "Gracell Biotechnologies Doses First Patient in Phase 1b/2 Clinical Trial in U.S. Evaluating GC012F for Treatment of Relapsed/Refractory Multiple Myeloma" Link

**"Janssen Launches National Campaign** to Recognize and Increase Support for Advanced Practice Providers Who Care for People Living with Multiple Myeloma" <u>Link</u>

**"Karyopharm** to Present **Selinexor** Data at the **2023 International Myeloma Society Annual Meeting** and European Society of Gynaecological Oncology 2023 Annual Meetings" <u>Link</u>

C "9/11 and cancer: NJ patients struggle with myeloma years after exposure to Ground Zero" Link

C (continued)

"BioLineRx Announces FDA Approval of APHEXDA™ (motixafortide) in Combination with Filgrastim (G-CSF) to Mobilize Hematopoietic Stem Cells for Collection and Subsequent Autologous Transplantation in Patients with Multiple Myeloma" Link

**D** "AbbVie Presents Results from Phase 3 CANOVA Study of Venetoclax in Patients with Relapsed or Refractory Multiple Myeloma" Link

"Mezigdomide Combos Yield Encouraging Responses in R/R Multiple Myeloma"  $\underline{\text{Link}}$ 

"Institute for Myeloma & Bone Cancer Research Announces Publication in Targeted Oncology" <u>Link</u>





## Articles per theme



### B-cell lymphoma 2 (BCL-2) inhibitor

**"AbbVie** Presents Results **from Phase 3 CANOVA** Study of Venetoclax in Patients with Relapsed or Refractory Multiple Myeloma" <u>Link</u>

### CAR-T

"Gracell Biotechnologies to Present Updated Clinical Data on BCMA/CD19 Dual-Targeting FasTCAR-T GC012F in Newly Diagnosed Multiple Myeloma at the 2023 International Myeloma Society Annual Meeting" Link

"Gracell Biotechnologies Doses First Patient in Phase 1b/2 Clinical Trial in U.S. Evaluating GC012F for Treatment of Relapsed/Refractory Multiple Myeloma" Link

### **CELMoD**

"Mezigdomide Combos Yield Encouraging Responses in R/R Multiple Myeloma" <u>Link</u>

## **Cyclic-peptide CXCR4 inhibitor**

"BioLineRx Announces FDA Approval of APHEXDA™ (motixafortide) in Combination with Filgrastim (G-CSF) to Mobilize Hematopoietic Stem Cells for Collection and Subsequent Autologous Transplantation in Patients with Multiple Myeloma" Link

## Nuclear export inhibitor (SINE)

"Karyopharm to Present Selinexor Data at the 2023 International Myeloma Society Annual Meeting and European Society of Gynaecological Oncology 2023 Annual Meetings" <u>Link</u>

## **HCPs/research support**

"Janssen Launches National Campaign to Recognize and Increase Support for Advanced Practice Providers Who Care for People Living with Multiple Myeloma" Link

"Multiple Myeloma Story Applied **Cells Opens CellQuest Research Grant** to Accelerate Cutting-Edge Multiple Myeloma
Research". Link

## **Patient support**

"Multiple Myeloma March returns to Cornwall Sept. 9"  $\underline{\mathsf{Link}}$ 

"9/11 and cancer: NJ patients struggle with myeloma years after exposure to Ground Zero" <u>Link</u>

### Research

"Immune system plays vital role in longer multiple myeloma remission, new study shows" <u>Link</u>

"Institute for Myeloma & Bone Cancer Research Announces Publication in Targeted Oncology" <u>Link</u>

# **Drug Market Watch**

September 2023



The combination therapy, DRT, has been approved for use in England and Wales for those with myeloma who are not eligible for a stem cell transplant Link





Pioneering treatment that could keep myeloma at bay for five years approved <u>Link</u>

The treatment combines three drugs – daratumumab (Darzalex®), lenalidomide (Revlimid®) and dexamethasone (DRD) – and is aimed at newly-diagnosed myeloma patients who are not eligible for a stem cell transplant.



BioLineRx Announces FDA Approval of

APHEXDA™ (motixafortide) in Combination
with Filgrastim (G-CSF) to Mobilize
Hematopoietic Stem Cells for Collection and
Subsequent Autologous Transplantation in
Patients with Multiple Myeloma Link

SYNDICATED By